Sofinnova Partners, an European life sciences venture capital firm based in Paris, London, and Milan, has closed the Sofinnova Digital Medicine I at $200 million, exceeding its target.
The fund was spearheaded by Partners Edward Kliphuis and Simon Turner. It is dedicated to backing pioneering entrepreneurs navigating the convergence of biology, data, and computation. Already, the fund has made investments into five revolutionary companies.
Sofinnova Digital Medicine I fund
The VC firm’s Digital Medicine Strategy arrives at a time when the healthcare sector is witnessing a transformation driven by digital advancements. The firm’s new fund focuses on three key areas, enabling technologies, analytics, and treatment.
The VC firm offers financial support, expertise, and extensive healthcare networks to entrepreneurs. It enables them to tackle global healthcare challenges and improve patient outcomes on a global scale.
Portfolio of recent investments
Sofinnova Digital Medicine recently added two companies to its portfolio:
L’école AI: The creator of a “machine teaching” technology, established by an ex-Twitter Cortex founding team member, simplifies the deployment of deep-learning systems for computer vision in life sciences applications.
Betteromics: The “Omics AI Cloud,” unifies disparate health and omics data into a single source of truth through a certified SaaS platform, backed by the expertise of its founding team from GRAIL, Verily and Google’s Search Knowledge Graph.
Boosts ambitious entrepreneurs
Led by Partners Edward Kliphuis, and Simon Turner, Sofinnova Partners managing over €2.5 billion aims to positively impact the future through innovative investments
The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact the collective future.
Antoine Papiernik, Sofinnova’s Chairman and Managing Partner, said: “The successful closing of Sofinnova Digital Medicine I above its target size marks yet another milestone in our growth as a global firm fostering disruptive innovations in life sciences. This newest fund in our platform of investment strategies is a testament to the trust our limited partners place in our vision and to Sofinnova’s long-standing commitment to shaping the future of healthcare.”
Edward Kliphuis, Partner, said: “In just a few months since launching this strategy, we’ve executed five investments into transformative companies, including Kiro, BioCorteX, deepc, L’école AI, and Betteromics, which are fusing state-of-the-art computational methods with advanced biological innovations. Leveraging our expertise and network, we serve as allies to digital medicine pioneers, enabling them to secure product-market fit and scale on a global stage.”
Simon Turner, Partner, said: “We bring Sofinnova’s deep healthcare expertise to entrepreneurs pioneering at the forefront of digital medicine where biology meets tech-industry approaches like rapid product iteration and accelerated commercialisation. Our goal is to support innovators developing disruptive solutions for patients and health systems.”
